Livzon Pharmaceutical Group (HK:01513) Drives Share Price Higher Amid Dividend Announcement
Livzon Pharmaceutical Group Inc. (HK:01513) posted a 1.47 % uptick in trading volume during the 24‑hour period ending at 02:50 PM Central Europe on Monday 26 November 2026. At the close, the shares traded at HK $22.66 on the main exchanges, reflecting a modest but steady climb from the previous day’s price.
Market Metrics
| Metric | Value |
|---|---|
| Shares Outstanding | 299.8 million |
| Market Capitalisation | HK $18.4 billion |
| 24‑hour Volume | HK $11 million |
| 200‑day Simple Moving Average | HK $26.11 |
| 52‑week High | HK $33.18 (14 Nov 2025) |
| 52‑week Low | HK $19.80 (31 Aug 2026) |
| Current Price | HK $22.66 |
| Percentage Change Since Month‑End | –3.09 % |
Dividend and Governance Update
In a decisive move to reinforce shareholder confidence, Livzon announced a third‑quarter profit distribution plan. The board proposes a cash dividend of 12.39 CNY per ten shares, a figure that aligns with the company’s broader strategy of balancing return on equity with continued investment in pipeline development.
The announcement coincided with a broader uptick in the pharmaceutical sector, as investors weighed the sector’s robust earnings momentum. Livzon’s share price advanced in line with peers such as Mloptic (688502.SS), which traded flat, and Dekon Food And Agriculture-H (2419.HK), which slipped slightly. The company’s trajectory is supported by a consistent upward trend in the 200‑day moving average, suggesting a bullish short‑term outlook.
An Extraordinary General Meeting (EGM) is slated for 12 November 2026. The EGM will address governance matters and potentially further financial decisions, including capital structure adjustments and strategic alliances. Market analysts anticipate that the EGM will reaffirm Livzon’s commitment to sustainable growth and shareholder value creation.
Peer Performance Snapshot
- Mloptic (688502.SS): Flat trading, CNY 347.05, market cap CNY 18.7 bn.
- Dekon Food And Agriculture-H (2419.HK): –0.87 % to HK $55.25, market cap HK $22 bn.
- China National Building Ma-H (3323.HK): +1.4 % to HK $2.87, market cap HK $22 bn.
- Hangzhou Turbine Power Group (300277.SZ): Flat, CNY 12.01, market cap CNY 18.7 bn, P/E 60.48.
- Opt Machine Vision Tech (688686.SS): Flat, CNY 148.77, market cap CNY 18.7 bn, P/E 86.52.
Opt Machine Vision Tech’s forthcoming quarterly results are expected to show an improvement in earnings per share, with revenue projected to rise proportionally. Although detailed figures remain undisclosed, the qualitative outlook signals continued growth in both profit and sales.
Forward‑Looking Perspective
Livzon’s strategic dividend policy and scheduled EGM position the company to capitalize on the resilient demand for pharmaceutical innovations in China and beyond. The firm’s diversified portfolio—encompassing chemical, biopharmaceutical, and patent‑Chinese medicines—provides a robust revenue base while sustaining pipeline development. With a market cap of HK $18.4 bn and a stable 200‑day moving average, Livzon is poised for incremental upside, provided it continues to navigate regulatory landscapes and maintain operational efficiency.
Investors should monitor the EGM outcomes for potential capital allocation decisions and assess how the company’s dividend policy will evolve in response to its earnings trajectory and strategic priorities.